| REVIEW ARTICLE |
|
| Year : 2016 | Volume
: 32
| Issue : 4 | Page : 271-276 |
|
|
Immunotherapy in metastatic prostate cancer
Susan F Slovin
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Correspondence Address:
Susan F Slovin
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-1591.191240
|
|
|
Introduction: Prostate cancer remains a challenge as a target for immunological approaches. The approval of the first cell-based immune therapy, Sipuleucel-T for prostate cancer introduced prostate cancer as a solid tumor with the potential to be influenced by the immune system.
Methods: We reviewed articles on immunological management of prostate cancer and challenges that lie ahead for such strategies.
Results: Treatments have focused on the identification of novel cell surface antigens thought to be unique to prostate cancer. These include vaccines against carbohydrate and blood group antigens, xenogeneic and naked DNA vaccines, and pox viruses used as prime-boost or checkpoint inhibitors. No single vaccine construct to date has resulted in a dramatic antitumor effect. The checkpoint inhibitor, anti-CTLA-4 has resulted in several long-term remissions, but phase III trials have not demonstrated an antitumor effect or survival benefit.
Conclusions: Multiple clinical trials suggest that prostate cancer may not be optimally treated by single agent immune therapies and that combination with biologic agents, chemotherapies, or radiation may offer some enhancement of benefit. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
